Brazil has announced the launch of its first national vaccine against dengue. With an expected production of 60 million annual doses from 2026, the inoculant developed by the Butantan Institute will be a single-dose vaccine effective against four virus serotypes. In 2024, the Pan American Health Organization (PAHO) reported that there were almost 13 million cases in the Americas, marking the greatest epidemic since records began in 1980.

The Brazilian Ministry of Health stated that the vaccine production will be carried out in association with the Chinese company Wuxi Biologics. The National Health Surveillance Agency (Anvisa) will supervise the registration for application in people between 2 and 59 years. Officials also indicated that they are still developing studies to expand the age range and evaluate its combination with other vaccines.

In 2024, the Americas not only recorded a historical maximum of cases but also counted 22,684 serious cases and 8,186 deaths (with a lethality of 0.063 percent), according to PAHO. Brazil, the most affected nation, along with Argentina, Colombia, and Mexico, concentrated 90 percent of cases and 88 percent of deaths, said the organization.

According to the Federal Government, during an event at the Palacio do Planalto in Brasilia, headed by President Luiz Inácio Lula da Silva and Minister of Health Nísia Trindade, the development of the vaccine is part of the local development and innovation program (PDIL). This program aims to strengthen the national industry and guarantee autonomy in access to health technologies. The vaccine will be distributed through the single health system (SUS).

The official also emphasized that this progress will allow an increase in the production capacity of dengue vaccines in the country by 50 times.

According to the Brazilian government agency, the Butantan Institute, responsible for the development, will carry out clinical studies to expand the age range of beneficiaries and evaluate the co-administration with other vaccines, such as Chikungunya.

According to the latest data disseminated by PAHO, in the Epidemiological Week 5 of 2025, 23 countries and territories reported 238,659 new suspected cases. Brazil concentrated 87 percent of cases, followed by Colombia (5.6 percent), Nicaragua (2.5 percent), Peru (2.5 percent), and Mexico (2.5 percent).

Despite a global decrease of 54 percent compared to the same period in 2024, the number of infections remains 25 percent higher than the average of the last five years. In the first weeks of 2025, 105 cases were classified as serious with 18 registered deaths in the last reported week. The lethality rate in 2025 has remained at 0.017 percent in week 5 with an accumulated rate of 0.028 percent so far this year, showing a slight reduction compared to the previous year.

Meanwhile, in the Andean subregion, cases increased in Ecuador (31 percent) and Peru (25 percent) compared to their previous weeks. In Central America and Mexico, the variation was 9 percent above the average of the last five years, while in the Caribbean, a general case drop was observed, except in Guadalupe, which reported a 65 percent increase. The Southern Cone recorded 94,317 new suspected cases in the last reported week, representing a 55 percent reduction compared to the same period in 2024 but an increase of 28 percent in relation to the average of five years.

PAHO has reiterated the importance of prevention strategies to curb the spread of the virus. Among the main recommended measures are strengthening epidemiological surveillance, training of health personnel, and mosquito control of the Aedes aegypti by proper handling of waste and larvae hatcheries.

In the United States, the Centers for Disease Control and Prevention (CDC) has also emphasized the importance of mosquito control and public awareness. The CDC recommends using insect repellent, wearing long sleeves and pants, and eliminating standing water where mosquitoes breed. The development of a dengue vaccine in Brazil could provide valuable insights and potential collaboration opportunities for the U.S. in combating this global health threat.

The successful development and distribution of the dengue vaccine in Brazil could serve as a model for other countries facing similar public health challenges. The vaccine’s effectiveness against all four serotypes of the dengue virus is a significant advancement, as previous vaccines have only targeted specific serotypes. This could lead to broader immunity and reduced transmission rates.

However, some experts caution that the vaccine’s success will depend on widespread adoption and effective distribution. Challenges such as vaccine hesitancy and logistical hurdles in reaching remote or underserved communities could impede its impact. Additionally, the co-administration of the dengue vaccine with other vaccines, such as Chikungunya, will require further research to ensure safety and efficacy.

In conclusion, Brazil’s launch of its first national dengue vaccine marks a significant milestone in the global fight against this debilitating disease. With the potential to produce 60 million doses annually by 2026, this vaccine could play a crucial role in reducing the burden of dengue in the Americas and beyond. The collaboration between the Butantan Institute and Wuxi Biologics, along with the support of the Brazilian government, highlights the importance of international partnerships in advancing public health initiatives. As the world continues to grapple with emerging infectious diseases, the lessons learned from Brazil’s vaccine development could inform future efforts to combat dengue and other global health threats.